Haleon plc (NYSE:HLN) is
one of the 15 successful spin-off companies. On July 4, the company broke ground on a new £130m Global Oral Health Innovation Center. The company is developing a state-of-the-art facility that focuses on enhancing scientific capabilities, accelerating innovation, and serving as a center for global oral health research.
George Rudy/Shutterstock.com
The construction of the £130m Global Oral Health Innovation Centre is part of Haleon’s focus on reaching over one billion consumers by 2030. The center is designed to pioneer research, drive product innovation, achieve commercial and supply chain excellence, and foster cross-functional collaboration.
Jayant Singh, Global Category Lead, Oral Health, and Haleon, said: “With oral diseases affecting nearly half the world’s population, this marks an exciting step forward in our mission to put health in more hands for millions across the world. This centre will play a key role in harnessing the full potential of science and innovation across our oral health portfolio.”
Established as a corporate spin-off from GSK, Haleon plc (NYSE:HLN) has evolved into a global leader in consumer health. Its product portfolio spans six major categories – Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health, Therapeutic Skin Health, and Others.
While we acknowledge the potential of HLN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the
best short-term AI stock.
READ NEXT: 12 Best Consumer Goods Stocks Billionaires Are Quietly Buying and Goldman Sachs Penny Stocks: Top 12 Stock Picks.
Disclosure: None. This article is originally published at
Insider Monkey.
